FDA advisory committees
Non-voting industry representatives will be added to all Center for Biologics Evaluation & Research and Center for Drug Evaluation & Research advisory committees. The FDA Modernization Act requires industry representatives for newly formed advisory committees. "Although not required for existing committees," FDA said it would add non-voting representatives "to keep within the spirit of FDAMA." An Aug. 16 Federal Register notice requests nominations
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth